## CI: The Cigna Group - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 0.53 indicates fundamental undervaluation. Quality metrics strong (ROE 16%). Consistent execution (3/4 quarters beat estimates). Caution: momentum weakening (-2.9% MRS).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($248.09)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 4
- **Sentiment:** Bullish (Bullish: 0, Bearish: 0)

**1. 14 Best US Stocks to Buy for Long Term**
- Source: Insider Monkey | 20251207T072600 | Neutral | Relevance: 65%
-  This article identifies Vistra Corp. (NYSE:VST) as one of the best US stocks for long-term investment, citing its strong cash flow, diversified generation mix, and strategic acquisitions. KeyBanc initiated coverage with an Overweight rating, and S&P Global upgraded its credit rating, highlighting the company's improved risk profile and growth potential in a tightening U.S. power market. Vistra is expanding its energy footprint through acquisitions and new natural gas power unit constructions.

**2. 12 Cheap Healthcare Stocks to Buy Heading into 2026**
- Source: Insider Monkey | 20251208T133100 | Somewhat-Bullish | Relevance: 64%
-  This article is part of a list detailing cheap healthcare stocks to consider for investment heading into 2026. It highlights Concentra Group Holdings Parent, Inc. (NYSE:CON), discussing its financial performance, analyst ratings, and growth prospects. The company reported significant increases in revenue, net income, and adjusted EBITDA in its third quarter.

**3. 14 Best US Stocks to Buy for Long Term**
- Source: Insider Monkey | 20251208T020842 | Somewhat-Bullish | Relevance: 63%
-  This article is part of a larger list identifying the best US stocks for long-term investment. It highlights The Goldman Sachs Group, Inc. (NYSE: GS) as a key contender, detailing its strategic acquisition of Innovator Capital Management to expand its asset management business, particularly in the growing defined-outcome ETFs market. The move reflects Goldman Sachs' broader efforts to diversify revenue streams beyond investment banking and trading.

**4. Certain Class B Ordinary Shares of Vantage Corp are subject to a Lock-Up Agreement Ending on 9-DEC-2025.**
- Source: marketscreener.com | 20251208T200852 | Neutral | Relevance: 62%
- Certain Class B Ordinary Shares of Vantage Corp are subject to a lock-up agreement that ends on December 9, 2025. This lock-up period spans 181 days, from June 11, 2025, to December 9, 2025. Directors, officers, and principal shareholders have agreed not to sell or transfer their Class A Ordinary Shares or related securities for 180 days after the prospectus date.

### Analyst Activity

**Target Signal:** VERY_BEARISH (Raises: 0, Lowers: 1)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-11-12 | Bernstein | $294 | $346 | -15% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-11-12 | Bernstein | main | Market Perform |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_BUYING** |
| Buys | 2 ($1.01M) |
| Sells | 2 ($0.00M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 48.7% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 4 |

**Top Holders:**
- Vanguard Group Inc: 9.6% (+0.1%)
- Blackrock Inc.: 8.3% (-1.1%)
- JPMORGAN CHASE & CO: 5.0% (+106.4%)
- State Street Corpora: 4.5% (-1.2%)
- Price (T.Rowe) Assoc: 4.2% (+9.8%)

### Key Risks

1. Momentum deterioration: MRS_20 falling (-2.9% 5d) with bearish MACD, trend may be turning.
2. Long-term trend broken: trading 13.4% below SMA200.
3. Market regime shift could impact momentum names disproportionately.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 0.53 indicates undervaluation relative to growth. Forward P/E 8.5x stretched relative to 4% growth. Balance sheet: $3.1B free cash flow. Analyst sentiment negative (1 target cuts vs 0 raises). Insider buying signal ($1.0M), management confidence. Institutional flow bullish (6 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $70.2B |
| Beta | 0.26 |
| 52W Range | $239.51 - $350.00 |
| Short Interest | 1.9% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.53 |
| Forward P/E | 8.5 |
| Current P/E | 8.9 |
| YoY Growth | 3.8% |
| EPS Direction | STABLE |

### Technicals

MRS_20 deteriorating from -2.3% to -5.2% (-2.9% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 9.2pp (needs >4.0% for momentum thesis). AM_20 at -3.1% indicates price below own 20MA trend. Below SMA200 (0.87x), long-term trend not supportive.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -5.19% (CS: 16) | Weak |
| RSI_14 | 39.3 | Neutral |
| MACD Histogram | -0.39 | Bearish |
| vs SMA20 | 0.968x | Below |
| vs SMA50 | 0.930x | Below |
| vs SMA200 | 0.866x | Below |

### Decision

- **Verdict:** HOLD
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $262.71
- **Stop Loss:** $248.09 (5.6% risk)
- **Target:** $291.95 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 20
- **Position Value:** $5,254.20
- **Portfolio %:** 5.25%
- **Risk Dollars:** $300.00
- **Risk Per Trade:** 0.30%
- **Modifiers:** L1 100% | L2 25% | Combined 0.30x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | TOXIC (Zone G) | 0.25x |

*NORMAL regime with moderate risk appetite. VIX remains in the mid-range, breadth is moderate, and yield curve is flat but not invertedâ€”indicating standard late-cycle conditions. Upbeat earnings and positive tech momentum are offset by cautious guidance in consumer sectors, suggesting selective positioning is favored.*

### Earnings

**Next:** 2026-02-05 (Est: $7.90)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $7.64 | $7.83 | +2.5% |
| 2025Q2 | $7.15 | $7.20 | +0.6% |
| 2025Q1 | $6.35 | $6.74 | +6.2% |
| 2024Q4 | $7.82 | $6.64 | -15.1% |

---
*RULE-based L3 | 2026-01-06 16:36 | MRS_20*